New hope for tough pancreatic cancer: experimental drug targets tumors
NCT ID NCT07561463
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks and aims to shrink tumors or slow the disease. Researchers will also check how well the drug works based on a protein called TROP-2 in the tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.